Back to home Back to home

Our Story

Learn more about our founder and history to deliver best practice mental healthcare and performance solutions through our global network

Empowering best practice since 2015

"We listened to the need of clinicians and patients telling us clinical practice needs to become more psychosomatic and empower them to use innovation such as rTMS or integrate sleep. In OECD countries only about 25% of patients have access to therapy. Our DTP addresses both issues - better clinician outcomes and better access for patients."

Tom Mechtersheimer - Founder & CEO, neurocare

digitalized-best-practice-platform-for-third-parties-and-neurocare-clinics

Our Best Practice Platform

Learn more

neurocare’s proprietary platform empowers clinicians to deliver best practice by integrating technology, training, software and services. This gives clinicians the tools to address the underlying cause of mental illness, harnessing the brain’s natural ability to rewire for lasting change.

We are able to test and develop this in our own clinics with growth and expansion planned across all regions and in new locations. We embrace and integrate all innovative and proven services from neuroscience and mental health, and look to future treatments, such as psychedelics, so we can embed them in our platform with the best effects.

Best outcomes for patients

assessment-personlisedtherapyplan-bestoutcomes

The cornerstone of neurocare treatments is to offer fully personalised and best practice services, factoring in brain activity, sleep, biomarkers and other lifestyle factors and metrics to deliver a completely tailored and individualised program. We are pioneers in now long-established neuromodulation methods such as TMS (Transcranial Magnetic Stimulation) and Neurofeedback and offer these in our clinics as well as training to other professionals via our platform.

We embrace and integrate all innovative and proven services from neuroscience and mental health. We are active in science, technology manufacturing and further development of SOPs in our leading clinics worldwide. We are already active in the space of psychedelics and look to future integrations within our platform to empower more and more clinicians to deliver these innovative services, more effectively, sustainably and with the best commercial outcomes.

The journey so far...

2000

Klaus Schellhorn forms spin-off from the Department of Biomedical Engineering of the Technical University of Ilmenau in Germany, this later becomes our Technology brand, neuroConn.

2001

Brainclinics Psychology practice is founded in Nijmegen, The Netherlands by Dr Martijn Arns which later forms the basis of our clinics and academy division.

Brainclinics logo

2002

Kerstin Wendicke & Hannes Zantow founded MAG & More in Munich, Germany, as a spin-off from the TU Munich and developed strong and reliable stimulators as well as new stimulation coils.

2004

First QEEG informed Neurofeedback delivered to patients with ADHD in The Netherlands.

Brainclinics Education offers professional training in Neurofeedback.

2006

Brainclinics is the first in Europe to treat depression with TMS in an outpatient setting.

Klaus Schellhorn and team launch product brand neuroConn.

2008

Brainclinics Education offers training in rTMS to other professionals.

2015

neurocare was founded in 2015 by Tom Mechtersheimer, bringing together leading neuroscience, technology manufacturers, processes and education for mental health clinics. Since this time we have expanded our operations in Australia, the United States and in Europe.

A Headquarters is established in Munich, Germany.

2016

neurocare opens new clinics in The Netherlands and expands to Australia, with the first clinic and regional head office in Sydney.

We also offer our first professional training workshops in the Asia Pacific.

2017

neurocare opens first clinics in the United States with a center in Medford, Long Island.

neurocare expands in Australia acquiring clinics in Frenchs Forest (NSW) and Balwyn (Victoria). Our DC-STIMULATOR tDCS technologies get approval by the Therapeutic Goods Administration (TGA) in Australia.

Insurance providers in the Netherlands start reimbursing for rTMS treatment for depression. neurocare expands clinics in The Netherlands, opening in Groningen and Hengelo.

2018

neurocare expands in Australia with a new clinic in East Melbourne.

neurocare opens a new clinic in The Netherlands, in Eindhoven

neurocare Centers of America opens a new locations in Medford, Long Island and Franklin / Cool Springs, Nashville.

2019

Our Frenchs Forest clinic in Australia relocates to larger premises.

neurocare opens a new clinic in The Hague in The Netherlands.

neurocare Centers of America opens a new location in Green Hills, Nashville.

2020

In response to the COVID-19 pandemic neurocare expands its services into digital and remote health solutions and the neurocare academy launches its online platform, the first online learning platform for professionals in neuromodulation.

2021

neurocare also acquires leading TMS device manufacturer MAG & More.

In Australia, our East Melbourne clinic relocates to larger premises and rTMS becomes reimbursed as a treatment for Depression in Australia under public health.

neurocare in The Netherlands expands its clinic in The Hague as well as opening new clinics in Arnhem and Amsterdam.

neurocare Centers of America opens a new location in Midtown, Nashville.

2022

Our Apollo and PowerMAG TMS systems receive approval by the TGA in Australia.

neurocare Centers of America opens a new location in Murfreesboro, Nashville and Knoxville, TN.

2024

neurocare opens a further clinic in Long Island in Levittown.

neurocare acquires Smart TMS clinics with nine clinics throughout the UK and Ireland, including Birmingham, Bristol, Dublin, Edinburgh, London, Manchester, Northampton, Southampton and St Albans.

Contact